|42.62||-1.65||-3.73%||Vol 78.47K||1Y Perf -19.16%|
|Apr 19th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||48.00||Analyst Rating||Moderate Buy 2.33|
|Potential %||12.62||Finscreener Ranking||★★★★+ 56.48|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★★ 57.33|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★+ 64.13|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Market Cap||563.31M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||31.20||Earnings Date||10th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th May 2021|
|Estimated EPS Next Report||0.20|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||99.32K|
|Avg. Monthly Volume||122.24K|
|Avg. Quarterly Volume||123.53K|
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) stock closed at 42.62 per share at the end of the most recent trading day (a -3.73% change compared to the prior day closing price) with a volume of 78.57K shares and market capitalization of 563.31M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 108 people. Eagle Pharmaceuticals Inc. CEO is Scott L. Tarriff.
The one-year performance of Eagle Pharmaceuticals Inc. stock is -19.16%, while year-to-date (YTD) performance is -8.48%. EGRX stock has a five-year performance of 13.62%. Its 52-week range is between 36.48 and 56.16, which gives EGRX stock a 52-week price range ratio of 31.20%
Eagle Pharmaceuticals Inc. currently has a PE ratio of 50.90, a price-to-book (PB) ratio of 3.15, a price-to-sale (PS) ratio of 4.13, a price to cashflow ratio of 12.30, a PEG ratio of 2.32, a ROA of 4.52%, a ROC of 2.92% and a ROE of 6.29%. The company’s profit margin is 11.09%, its EBITDA margin is 12.10%, and its revenue ttm is $141.78 Million , which makes it $10.73 revenue per share.
Of the last four earnings reports from Eagle Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.20 for the next earnings report. Eagle Pharmaceuticals Inc.’s next earnings report date is 10th May 2021.
The consensus rating of Wall Street analysts for Eagle Pharmaceuticals Inc. is Moderate Buy (2.33), with a target price of $48, which is +12.62% compared to the current price. The earnings rating for Eagle Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Eagle Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Eagle Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.98, ATR14 : 2.04, CCI20 : 37.95, Chaikin Money Flow : -0.03, MACD : -1.04, Money Flow Index : 48.12, ROC : 2.11, RSI : 49.58, STOCH (14,3) : 60.17, STOCH RSI : 0.36, UO : 53.56, Williams %R : -39.83), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Eagle Pharmaceuticals Inc. in the last 12-months were: Scott L. Tarriff (Option Excercise at a value of $273 945), Steven B. Ratoff (Option Excercise at a value of $10 343)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.